We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

268 hedge funds and large institutions have $5.5B invested in Array Biopharma Inc in 2019 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 101 increasing their positions, 75 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

338% more call options, than puts

Call options by funds: $89.5M | Put options by funds: $20.4M

114% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 29

83% more capital invested

Capital invested by funds: $3B → $5.5B (+$2.5B)

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

35% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 75

14% more funds holding

Funds holding: 236 → 268 (+32)

Holders
268
Holders Change
+32
Holders Change %
+13.56%
% of All Funds
5.8%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.28%
New
62
Increased
101
Reduced
75
Closed
29
Calls
$89.5M
Puts
$20.4M
Net Calls
+$69.1M
Net Calls Change
+$50.4M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$123M
2
PA
Perceptive Advisors
New York
+$88M
3
MWNA
Marshall Wace North America
New York
+$52.9M
4
ACA
Avoro Capital Advisors
New York
+$41.6M
5
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$33.4M

Top Sellers

1
RG
Redmile Group
California
-$114M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84M
3
Millennium Management
Millennium Management
New York
-$30.8M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$30.7M
5
BI
BVF Inc
California
-$27.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
DTL
276
Dynamic Technology Lab
Singapore
– -$685K -48,058 Closed
WAM
277
Wolverine Asset Management
Illinois
– -$618K -43,384 Closed
QSS
278
Quantitative Systematic Strategies
Florida
– -$502K -35,249 Closed
Balyasny Asset Management
279
Balyasny Asset Management
Illinois
– -$450K -31,579 Closed
FRM
280
Fox Run Management
Connecticut
– -$447K -31,397 Closed
JMPWA
281
JP Morgan Private Wealth Advisors
California
– -$286K -20,050 Closed
PP
282
Paloma Partners
Connecticut
– -$276K -19,400 Closed
KAM
283
Kazazian Asset Management
Florida
– -$222K -15,564 Closed
Simplex Trading
284
Simplex Trading
Illinois
– -$246K -11,808 Closed
GCP
285
GSA Capital Partners
United Kingdom
– -$166K -11,674 Closed
BBI
286
Baxter Bros Inc
Connecticut
– -$145K -10,200 Closed
IA
287
IFP Advisors
Florida
– -$40K -2,831 Closed
ED
288
Exane Derivatives
France
– -$39.4K -2,763 Closed
PCM
289
Prelude Capital Management
New York
– -$27K -1,927 Closed
CG
290
Cutler Group
California
– -$31.2K -1,500 Closed
ER
291
Enlightenment Research
Florida
– -$19K -1,300 Closed
MWA
292
Meridian Wealth Advisors
Texas
– -$14K -1,000 Closed
AIC
293
Ameritas Investment Company
Nebraska
– -$7K -500 Closed
NIT
294
NumerixS Investment Technologies
British Columbia, Canada
– -$4K -300 Closed
Carson Wealth (CWM LLC)
295
Carson Wealth (CWM LLC)
Nebraska
– -$1K -99 Closed
WTC
296
WhitTier Trust Company
Nevada
– -$1K -42 Closed
8 9 10 11
12

ARRY Hedge Fund Activity: Q1 2019 in Review

268 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2019, worth a combined $5.5B — up 83% from $3B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new ARRY positions and 29 closed out — a net gain of 33 holders — while 101 added to existing stakes and 75 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was Redmile Group, cutting an estimated $114M.

  • 268 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2019, up from 236 in Q4 2018.
  • Funds reported $5.5B of Array Biopharma Inc stock for Q1 2019, up 83% quarter-over-quarter.
  • 62 funds opened new Array Biopharma Inc positions in Q1 2019 and 29 closed out, a net change of +33 holders.
  • The largest Array Biopharma Inc buyer in Q1 2019 was T. Rowe Price Associates, an estimated $123M added.
  • The largest Array Biopharma Inc seller in Q1 2019 was Redmile Group, an estimated $114M sold.

Based on aggregated 13F filings for Q1 2019.